scPharmaceuticals

scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

scPharmaceuticals reports Q4 loss, sees growth potential with FUROSCIX

scPharmaceuticals' financials show investment in the FUROSCIX launch, with a net loss reported for Q4 2022 and the full year.
FUROSCIX's commercial success, distribution partnerships, and evolving physician perceptions are key strengths for the company.
Challenges lie in reimbursement processes, achieving target co-pays, and aligning on optimal FUROSCIX use timing among doctors.
Opportunities include the substantial market potential, targeted outreach to hospitals, and driving prescriptions through in-services.

scPharmaceuticals reports mixed Q1 results, FUROSCIX shows promising market reception

scPharmaceuticals reported mixed financials with strong revenue but a net loss in Q1 2023.
FUROSCIX's success in the market and positive feedback position it well for future growth.
Challenges exist in managing expenses and securing broader coverage for the treatment.
Opportunities lie in expanding patient access, improving authorization rates, and driving revenue growth.

scPharmaceuticals reports $1.6M Q2 revenue, eyes FDA filing expansion

scPharmaceuticals (SCPH) reported mixed financial results for Q2, with strong revenue but a net loss. The company is focused on expanding FUROSCIX's market reach, improving gross to net discount, and enhancing brand awareness through marketing efforts. Anticipated FDA filing and plans for indication expansion signal growth potential.

scPharmaceuticals reports stellar Q3 performance, eyes market expansion opportunities

scPharmaceuticals delivered robust financial results in Q3 2023, driven by strong revenue growth and improved gross profit margins.
Strategic initiatives to expand market reach and access to FUROSCIX position the company for sustained growth and market penetration.
While facing challenges in pricing dynamics and regulatory expansions, scPharmaceuticals holds significant opportunities for growth and value creation.

scPharmaceuticals reports strong Q4 earnings and eyes market expansion

scPharmaceuticals showcased robust financial performance and strategic growth initiatives in Q4 2023, driven by FUROSCIX sales.
While facing market complexities and operational challenges, the company maintains a strong cash position and optimistic outlook for future initiatives.
Opportunities lie in market access negotiations, streamlined regulatory processes, and expanding product coverage, positioning scPharmaceuticals for continued success.

scPharmaceuticals reports Q1 challenges but remains optimistic for 2024

scPharmaceuticals faced challenges in Q1 due to a cyber attack and increased expenses, but showed resilience with positive trends in FUROSCIX utilization and growth initiatives. The company remains optimistic for continued momentum and life cycle initiatives in 2024.

scPharmaceuticals reports robust Q2 performance and regulatory wins

scPharmaceuticals delivered strong financial performance and regulatory milestones in Q2 2024, positioning the company for growth.
While facing operational challenges and competitive pressures, the company's strategic strengths and opportunities offer avenues for future success.
With a focus on innovation, market expansion, and financial stability, scPharmaceuticals is poised for continued growth and value creation.
Investors can be optimistic about scPharmaceuticals' progress and potential in the pharmaceutical market based on the Q2 performance and strategic initiatives.

scPharmaceuticals reports revenue growth and strategic advancements in Q3

scPharmaceuticals demonstrated revenue growth and strategic advancements in Q3 2024, underpinned by strong FUROSCIX sales and key initiatives.
While facing challenges such as ongoing losses and pricing dynamics, the company's focus on innovation and commercial progress positions it well for future growth.
With opportunities in seasonal demand, market expansion, and a solid financial base, scPharmaceuticals is poised for continued development and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Announced launch and commercial availability of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Management to host conference call and webcast at 4:30 p.m. ET

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22

BURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in a fireside chat at the Cowen 43rd Annual Health Care Conference, on Wednesday, March 8 at 10:30 am ET in Boston. Mr. Tucker will also be meeting with investors March 6 – 8.

scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care Conference

BURLINGTON, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced the launch and commercial availability of FUROSCIX®, a proprietary formulation of furosemide delivered via an on-body infusor for the outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure. FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema. The FUROSCIX Infusor will deliver only an 80-mg dose.

scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX® (furosemide injection)

scPharmaceuticals, Inc. (SCPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Recent Price Trend in scPharmaceuticals, Inc. (SCPH) is Your Friend, Here's Why

BURLINGTON, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to present virtually at the SVB Securities Global Biopharma Conference, on Thursday, February 16 at 11:20 am ET. Mr. Tucker will also be meeting virtually with investors on that day.

scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

Commercial launch planned for February 20, 2023 Commercial launch planned for February 20, 2023

scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update

scPharma is a small-cap biotech with a cardiology product, Furoscix, that was approved last October, expected to launch in 1Q 2023. We believe Furoscix is derisked as furosemide (loop diuretics) is the current standard of care, and the value proposition of SC dosage (over IV) is clear.

scPharmaceuticals: Undervalued, De-Risked Cardiology Commercial Biotech, Initiating With A Buy

scPharmaceuticals, Inc. (SCPH) Is a Great Choice for 'Trend' Investors, Here's Why

scPharmaceuticals, Inc. (SCPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes scPharmaceuticals, Inc. (SCPH) a New Buy Stock

Here is how scPharmaceuticals, Inc. (SCPH) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.

Has scPharmaceuticals (SCPH) Outpaced Other Medical Stocks This Year?

The average of price targets set by Wall Street analysts indicates a potential upside of 163.7% in scPharmaceuticals, Inc. (SCPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 164% Upside in scPharmaceuticals, Inc. (SCPH): Can the Stock Really Move This High?

Appointment brings more than 20 years of life sciences finance leadership experience to the CFO role Appointment brings more than 20 years of life sciences finance leadership experience to the CFO role

scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer

BURLINGTON, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in the 12th Annual LifeSci Partners Corporate Access Event, on Monday, January 9 and Tuesday, January 10, 2023, in San Francisco. Learn more about the event and schedule an in-person meeting with the scPharmaceuticals management here.

scPharmaceuticals to Participate in the 12th Annual LifeSci Partners Corporate Access Event

BURLINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 6,620,000 shares of its common stock at a public offering price of $5.25 per share and, to an investor in lieu of common stock, a prefunded warrant to purchase up to 2,905,000 shares of common stock at a purchase price of $5.249 per underlying share, for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses and excluding the exercise of the pre-funded warrant. The prefunded warrant has an exercise price of $0.001 per share.  All of the shares and the prefunded warrant are being offered by scPharmaceuticals. The offering is expected to close on November 25, 2022, subject to the satisfaction of customary closing conditions.

scPharmaceuticals Announces Pricing of $50 Million Public Offering

BURLINGTON, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a proposed underwritten public offering of shares (“Shares”) of its common stock (the “Offering”). All Shares to be sold in the Offering will be offered by scPharmaceuticals. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering.

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q3 2022 Results Conference Call November 9, 2022 4:30 PM ET Company Participants Hans Vitzthum - IR John Tucker - CEO Rachael Nokes - SVP, Finance Steve Parsons - VP, Head of Commercial Conference Call Participants Roanna Ruiz - SVB Securities Glen Santangelo - Jefferies Douglas Tsao - H.C. Wainwright Naz Rahman - Maxim Group Operator Greetings, and welcome to the scPharmaceuticals Third Quarter 2022 Earnings Call.

scPharmaceuticals Inc. (SCPH) Q3 2022 Earnings Call Transcript

Announced FDA marketing approval of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure

scPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to present at the Jefferies London Healthcare Conference, on Wednesday, November 16 at 5:35 pm GMT (12:35 pm ET).

scPharmaceuticals to Participate in the Jefferies London Healthcare Conference

BURLINGTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals' management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 9, 2022, to discuss third quarter financial results and provide a business update.

scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

After two CRLs, FUROSCIX has finally received FDA approval. This treatment could be a game-changer in the treatment of heart failure, allowing certain patients to avoid costly hospitalizations altogether and simply self-administer treatment at home.

scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients

scPharmaceuticals (SCPH) receives FDA approval for its proprietary heart failure therapy. It also reported a debt refinancing agreement to help with the drug launch.

scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approval

There were not just one, but two press releases from scPharmaceuticals (NASDAQ: SCPH ) this morning. Apparently, the U.S. Food and Drug Administration (FDA) approved Furoscix.

Why Is scPharmaceuticals (SCPH) Stock in the Spotlight Today?

FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide

UPDATE - scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure

Funds to be used to facilitate U.S. commercial launch of FUROSCIX® Funds to be used to facilitate U.S. commercial launch of FUROSCIX®

News for scPharmaceuticals Stock (SCPH)